Comprehensive Review of Ustekinumab Utilization in Inflammatory Bowel Diseases: Insights from the ClinicalTrials.gov Registry

References

• Cleynen I, Linsen L, Verstockt S, et al. Inflammatory Bowel Disease (IBD)—A textbook case for multi-centric banking of human biological materials. Front Med. 2019;6:230. doi:10.3389/fmed.2019.00230
   Web of Science ®Google Scholar
• Gordon IO, Agrawal N, Willis E, et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther. 2018;47:922–939. doi:10.1111/APT.14526
   PubMed Web of Science ®Google Scholar
• Pimentel AM, Rocha R, Santana GO. Crohn’s disease of esophagus, stomach and duodenum. World J Gastrointest Pharmacol Ther. 2019;10:35. doi:10.4292/WJGPT.V10.I2.35
   PubMedGoogle Scholar
• Almuntashri F, Binyaseen K, Alkhotani A, Almuntashri F, Binyaseen K, Alkhotani A. Chronic inflammatory demyelinating polyneuropathy in patients with Crohn’s disease on infliximab therapy. Cureus. 2021;13. doi:10.7759/CUREUS.19041
   PubMedGoogle Scholar
• Bouchard D, Abramowitz L, Bouguen G, et al. Anoperineal lesions in Crohn’s disease: French recommendations for clinical practice. Techniq Coloproctol. 2017;21(9):683–691. doi:10.1007/s10151-017-1684-y
   PubMed Web of Science ®Google Scholar
• Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol. 2003;16:347–358. doi:10.1097/01.MP.0000064746.82024.D1
   PubMed Web of Science ®Google Scholar
• Schmid-Tannwald C, Agrawal G, Dahi F, Sethi I, Oto A. Diffusion-weighted MRI: role in detecting abdominopelvic internal fistulas and sinus tracts. J Magn Reson Imaging. 2012;35:125–131. doi:10.1002/JMRI.22804
   PubMed Web of Science ®Google Scholar
• Robert JR, Sachar DB, Greenstein AJ. Severe Gastrointestinal Hemorrhage in Crohn’s Disease. Ann Surg. 1991;213:207. doi:10.1097/00000658-199103000-00004
   PubMed Web of Science ®Google Scholar
• Fazio VW, Wilk P, Turnbull RB, Jagelman DG. The dilemma of Crohn’s disease: ileosigmoidal fistula complicating Crohn’s disease. Dis Colon Rectum. 1977;20:381–386. doi:10.1007/BF02587365/METRICS
   PubMedGoogle Scholar
• Ephgrave K. Extra-Intestinal Manifestations of Crohn’s Disease. Surg Clin North Am. 2007;87:673–680. doi:10.1016/J.SUC.2007.03.003
   PubMed Web of Science ®Google Scholar
• Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585–595. doi:10.1038/nrgastro.2013.117
   PubMed Web of Science ®Google Scholar
• Alharbi MH, Alhazmi AH, Ujaimi MH, et al. The prevalence of irritable bowel syndrome and its relation to psychiatric disorders among citizens of Makkah region, Saudi Arabia. Cureus. 2022;14. doi:10.7759/CUREUS.32705
   Web of Science ®Google Scholar
• Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26:349–355. doi:10.1053/J.SEMPEDSURG.2017.10.003
   PubMed Web of Science ®Google Scholar
• Coates MD, Lahoti M, Binion DG, Szigethy EM, Regueiro MD, Bielefeldt K. Abdominal pain in ulcerative colitis. Inflamm Bowel Dis. 2013;19:2207–2214. doi:10.1097/MIB.0B013E31829614C6
   PubMed Web of Science ®Google Scholar
• Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474–1482. doi:10.1038/AJG.2012.260
   PubMed Web of Science ®Google Scholar
• Khayyat Y. Perception of symptomatic abdominal bloating in irritable bowel syndrome among Saudi Arabian patients. J Umm Al-Qura Univ Med Sci. 2020;6:1–3. doi:10.54940/MS84929526
   Google Scholar
• Roda G, Chien Ng S, Kotze PG, et al. Crohn’s Disease. Nat Rev Dis Prim. 2020;6:1–19. doi:10.1038/s41572-020-0156-2
   PubMedGoogle Scholar
• Sandle GI. Pathogenesis of diarrhea in ulcerative colitis: new views on on old problem. J Clin Gastroenterol. 2005;39:S49–S52. doi:10.1097/01.MCG.0000155520.04253.37
   PubMed Web of Science ®Google Scholar
• Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94. doi:10.1128/CMR.15.1.79-94.2002
   PubMed Web of Science ®Google Scholar
• Okobi OE, Udoete IO, Fasehun OO, et al. A Review of four practice guidelines of inflammatory bowel disease. Cureus. 2021;13:8.
   Web of Science ®Google Scholar
• Crohn’s & Colitis FoundationThe Crohn’s & Colitis Foundation of America. THE FACTS ABOUT inflammatory bowel diseases 2014; 2014.
   Google Scholar
• The National Health Service Inflammatory Bowel Disease. Available from: https://www.nhs.uk/conditions/inflammatory-bowel-disease/. Accessed January 3, 2023.
   Google Scholar
• Kuhbacher T, Fölsch UR. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol WJG. 2007;13:1149. doi:10.3748/wjg.v13.i8.1149
   PubMed Web of Science ®Google Scholar
• Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-tumor necrosis factor-α induced systemic lupus erythematosus. Open Rheumatol J. 2012;6:315. doi:10.2174/1874312901206010315
   PubMedGoogle Scholar
• Arijs I, De Hertogh G, Lemmens B, et al. Effect of Vedolizumab (Anti-Α4β7-Integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67:43–52. doi:10.1136/GUTJNL-2016-312293
   PubMed Web of Science ®Google Scholar
• Liu E, Aslam N, Nigam G, Limdi JK. Tofacitinib and Newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going. Drugs Context. 2022;11:1–17. doi:10.7573/DIC.2021-11-4
   Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960. doi:10.1056/NEJMoa1602773
   PubMed Web of Science ®Google Scholar
• Bishop C, Simon H, Suskind D, Lee D, Wahbeh G. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2016;63:348–351. doi:10.1097/MPG.0000000000001146
   PubMed Web of Science ®Google Scholar
• Reich K, Yasothan U, Kirkpatrick P. Ustekinumab. Nat Rev Drug Discov. 2009;8:355–357. doi:10.1038/nrd2878
   PubMed Web of Science ®Google Scholar
• Osuna CG, Gómez-Vila B, Pariente JA, et al. Ustekinumab drug survival in patients with psoriasis: a retrospective study of real clinical practice. Med. 2020;56:584. doi:10.3390/MEDICINA56110584
   Google Scholar
• Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United Eur Gastroenterol J. 2020;8:91. doi:10.1177/2050640619895361
   PubMed Web of Science ®Google Scholar
• Weber J, Keam SJ. Ustekinumab. BioDrugs. 2009;23:53–61. doi:10.2165/00063030-200923010-00006
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson Janssen Announces U.S. FDA Approval of STELARA® (Ustekinumab) for the treatment of adults with moderately to severely active ulcerative. Available from: https://www.jnj.com/janssen-announces-u-s-fda-approval-of-stelara-ustekinumab-for-The-treatment-of-adults-with-moderately-to-severely-active-ulcerative. Accessed January 5, 2023.
   Google Scholar
• STELARA® (Ustekinumab). US FDA package insert; 2022.
   Google Scholar
• Quaresma AB, Damiao AOMC, Coy CSR, et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in brazil: a large population-based study. Lancet Reg Heal. 2022;13:100298.
   Google Scholar
• Juliao-Baños F, Kock J, Arrubla M, et al. Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients. Medicine. 2021;100. doi:10.1097/MD.0000000000024729
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology. 2022;162:1147–1159.e4. doi:10.1053/j.gastro.2021.12.282
   PubMed Web of Science ®Google Scholar
• Singh S, Qian AS, Nguyen NH, et al. Trends in US health care spending on inflammatory bowel diseases, 1996–2016. Inflamm Bowel Dis. 2022;28:364–372. doi:10.1093/ibd/izab074
   PubMed Web of Science ®Google Scholar
• Su H-J, Chiu Y-T, Chiu C-T, et al. Inflammatory bowel disease and its treatment in 2018: global and Taiwanese status updates. J Formos Med Assoc. 2019;118:1083–1092. doi:10.1016/j.jfma.2018.07.005
   PubMed Web of Science ®Google Scholar
• Choe JY, Choi S, Song KH, et al. Incidence and prevalence trends of pediatric inflammatory bowel disease in the Daegu-Kyungpook province from 2017 to 2020. Front Pediatr. 2022;2022:1600.
   Google Scholar
• Argyriou K, Kapsoritakis A, Oikonomou K, Manolakis A, Tsakiridou E, Potamianos S. Disability in patients with inflammatory bowel disease: correlations with quality of life and patient’s characteristics. Can J Gastroenterol Hepatol. 2017;2017. doi:10.1155/2017/6138105
   PubMed Web of Science ®Google Scholar
• Büsch K, Sonnenberg A, Bansback N. Impact of inflammatory bowel disease on disability. Curr Gastroenterol Rep. 2014;16:1–9. doi:10.1007/s11894-014-0414-0
   Google Scholar
• Le Berre C, Peyrin-Biroulet L, Buisson A, et al. Impact of inflammatory bowel diseases on working life: a French nationwide survey. Dig Liver Dis. 2019;51:961–966. doi:10.1016/j.dld.2019.01.024
   PubMedGoogle Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106. doi:10.1136/gutjnl-2019-318484
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohn’s Colitis. 2020;14:4–22. doi:10.1093/ecco-jcc/jjz180
   Google Scholar
• Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1465–1496. doi:10.1053/j.gastro.2020.01.007
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohn’s Colitis. 2022;16:2–17. doi:10.1093/ecco-jcc/jjab178
   Google Scholar
• STELARA® (Ustekinumab). US FDA Package Insert 2016; 2016.
   Google Scholar